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Vaccination with messenger RNA (mRNA)-transfected
dendritic cells (DCs) is a very potent and versatile strategy
for immune intervention. It has recently been reported to
trigger specific T-cell responses and clinical benefit when
used as anti-tumor vaccine in cancer patients. Towards the
improvement of this promising technology, most
researchers studied the optimal transfection methods,
maturation signals and application sites of DCs. On the
contrary, we focused our research on the improvement of
the other active component of this vaccine that is mRNA.
We studied the stability and efficiency of translation of
different mRNA designed to have improved futures.
Through this work, we could develop an optimal mRNA
vector called RNActive™ which enhances the efficiency of
mRNA-based immune stimulations. Besides, we tested
the possibility of replacing DCs by some other immune
cells as a recipient of the mRNA. We found that under cer-
tain conditions, mRNA can be transfected in PBMCs prep-
arations. The expression of relevant antigens through this
mRNA transfection technology results in the presentation
of MHC-associated epitopes as demonstrated by the stim-
ulation of antigen-specific T-cells. This method is a blood-
saving replacement of mRNA-transfected DCs. It is useful
especially in the context of immunomonitoring: a small
amount of PBMCs is enough to generate mRNA-trans-
fected autologous cells. These cells can be used as targets
in in vitro assays where the T-cell response that developed
in vaccinated patients is being studied. Thus, our work on
mRNA-technologies offers new tools to improve and
study the triggering of immune responses using mRNA-
based vaccines.
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